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Abstract. The purpose of this study was to assess the 
feasibility of imaging of bladder cancer with fluorine-18 
fluorodeoxyglucose positron emission tomography 
(FDG-PET) scanning. We studied 12 patients with histo- 
logically proven bladder cancer who had undergone sur- 
gical procedures and/or radiotherapy. Retrograde irriga- 
tion of the urinary bladder with 1000-3710 ml saline 
was performed during nine of the studies. Dynamic and 
static PET images were obtained, and standardized up- 
take value images were reconstructed. FDG-PET scan- 
ning was true-positive in eight patients (66.7%), but 
false-negative in four (33.3%). Of 20 organs with tumor 
mass lesions confirmed pathologically or clinically, 16 
(80%) were detected by FDG-PET scanning. FDG-PET 
scanning detected all of 17 distant metastatic lesions and 
two of three proven regional lymph node metastases. 
FDG-PET was also capable of differentiating viable re- 
current bladder cancer from radiation-induced altera- 
tions in two patients. In conclusion, these preliminary 
data indicate the feasibility of FDG-PET imaging in pa- 
tients with bladder cancer, although a major remaining 
pitfall is intense FDG accumulation in the urine. 
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Introduction 
Bladder cancer is one of the most common diseases 
treated by urologists, and is the fourth most common 
cause of cancer deaths in men after lung, prostate, and 
colorectal cancer, accounting for 5% of all cancer deaths 
in men in the United States [1]. Approximately 70% of 
bladder cancers are low-grade, superficial tumors, but 
the majority of patients develop tumor recurrences fol- 
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lowing endoscopic resection. Most patients with invasive 
bladder cancer already have invasive disease with occult 
distant metastases at the time of initial diagnosis [1]. A 
variety of clinical procedures and many imaging meth- 
ods are available in the management of bladder cancer. 
Some of them are routinely performed and are supposed 
to be useful diagnostic tools for staging bladder cancer. 
Abdominal ultrasonography, computed tomography 
(CT), and magnetic resonance imaging (MRI) are help- 
ful in detecting a tumor mass; however, for the purpose 
of staging they are not as accurate as pathological stag- 
ing [1-7]. 
Considerable errors arise when staging bladder can- 
cer with standard diagnostic methods, although accurate 
staging is very important in planning optimal therapy [1, 
2]. For example, the accuracy of CT scanning is limited 
because it can only detect gross extravesical tumor ex- 
tension. The presence of enlarged regional lymph nodes 
does not always indicate metastasis [3]. CT scans fail to 
detect lymph node metastases of bladder cancer in up to 
40% of patients with such metastases [4]. The accuracy 
of MRI is only 60%, using TNM staging. Most MRI 
studies point to the failure of this modality to adequately 
visualize lymphatic metastases [5]. Transurethral ultra- 
sonography is most valuable in determining the stage of 
tumor confined to the bladder wall [6]. However, it has 
limitations in detecting lymph node involvement and 
perivesical tumor extension. Thus, no single imaging 
method provides all of the necessary staging informa- 
tion. 
Positron emission tomography (PET) with the glu- 
cose analogue 2-deoxy-2-[18F]fluoro-D-glucose (FDG) 
has been increasingly used as a noninvasive, diagnostic 
imaging modality for various neoplasms [8-11]. FDG- 
PET can measure tissue metabolism, i.e., increased gly- 
colysis in neoplasm. There have been many published 
reports regarding FDG tumor metabolic imaging as a di- 
agnostic modality in many diseases. However, no inves- 
tigators have yet published the accuracy of FDG-PET in 
patients with bladder cancer, except for one case report 
which employed FDG-PET to obtain images of preoper- 
ative or recurrent bladder cancer [12, 13]. 
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The aim of this preliminary study was to assess the 
feasibility of imaging of tumors and their regional exten- 
sion by means of FDG-PET scanning. 
Materials and methods 
Patients'. We studied 12 patients (seven males, five females) with 
histologically proven bladder cancer between 1989 and 1994. 
Their ages ranged from 39 to 83 years, with a mean of 63.5 years. 
Of the 12 patients, seven had undergone transurethral resection of 
bladder tumor (TUR-BT), three cystoscopic biopsy, and two radi- 
cal cystectomy. Four patients had undergone radiotherapy and/or 
chemotherapy in addition to the surgical procedures. On average 
the therapies had been performed 2.7 months before FDG-PET 
study. The histopathologically proven diagnoses were: transitional 
cell carcinoma in ten cases (nine cases were grade 3, and one, 
grade 2), adenocarcinoma in one, and high-grade pteomorphic 
sarcoma in one. All patients had suspected recurrent or residual 
tumor at the time of the FDG-PET studies. FDG-PET study was 
thus employed to assess residual or recurrent tumor and its exten- 
sion, and to differentiate tumor recurrence from radiation-induced 
cystitis or necrosis. Final diagnoses were obtained by sequential 
surgical procedures in nine patients: radical cystectomy and ileal 
conduit in seven patients, emergency laparotomy in one patient 
with suspected peritoneal carcinomatosis, and aspiration biopsy of 
a lymph node in one. The duration between the original tissue di- 
agnosis and FDG-PET study was 2 weeks to 7 years, with an aver- 
age of 15.6 months. In the remaining three patients with distant 
metastases, the metastatic foci were diagnosed by other diagnostic 
imaging modatities and review of all available medical records for 
each patient. All of the patients were followed up after the FDG- 
PET study by the referring urologists and were monitored by 
chest X-ray, bone scintigraphy, and/or CT. 
Written informed consent was obtained from all of the patients 
after the study was explained to them in detail. The study had 
Internal Review Board (IRB) approval and was conducted under 
an Investigational New Drug (IND) accepted by the Food and 
Drug Administration for FDG. All but one patient fasted for ap- 
proximately 12 h before scanning; the remaining patient fasted for 
4 h. The serum glucose level was measured before and after scan- 
ning, and no patients were found to have high glucose leveis or di- 
abetes mellitus. We performed retrograde irrigation of the urinary 
bladder during the study in nine patients, by placing a double-lu- 
men Foley catheter (12 F), hanging a bag of sterile saline with 
1000-3750 ml for irrigation, and then draining the fluid to com- 
pletely empty the bladder. Postvoid FDG imaging after irrigation 
was performed in one patient. 
Imaging plvtocol. Fluorine-18 was prepared with a medical cyclo- 
tron (T.C.C. model CS-30 cyclotron, Berkeley, Calif.) by the ac- 
celeration of deutrons into an H21aO target. A nucleophilic fluori- 
nation procedure was used to produce FDG of high specific activi- 
ty (estimated to be greater than 3000 Ci/mmol) which was of 
greater than 95 % radiochemical purity [ 14]. 
All patients were studied with a whole-body eight-ring (15 
plane) positron emission scanner (Siemens CTI 931 or 921 PET 
scanner; these scanners had an axial field of view of approximate- 
ly 10.3 cm and 15 cm, respectively). The pixel size of the 931 and 
921 scanners was 0.469 and 0.422, respectively. Patients were po- 
sitioned supine and head first in the scanner gantry with arms 
above the head so that the arms and head were through the scan- 
ner gantry. Transmission scans using a germanium-68 source were 
performed at the level believed to include the mass lesion. After 
the transmission images had been obtained, the patient was posi- 
tioned so that the scanner field (approximately 20-cm field of 
view) was at the imaging level believed to include the mass; dy- 
namic scan acquisition over 60 min was then performed after in- 
travenous injection of approximately 10 mCi (370 MBq) FDG. A 
dynamic imaging sequence was used with 10-s acquisition frames 
during the initial 1 min, 20-s frames between 1 and 2 rain, 1.5-rain 
frames through 5 rain, a single 5-min frame through 10 min, and 
then sequential 10-min image frames through 60 or 70 min after 
injection. At 60-70 rain after injection the patient was reposi- 
tioned and the second imaging levels were examined for 10 rain. 
In addition, in two patients "whole-body" FDG images were ac- 
quired over 15 (three bed positions of 5 rain each) or 21 (seven 
bed positions of 3 rain each) min because of suspected multiple 
metastases to remote organs. 
PET images were reconstructed from projection data, and 
transaxial, coronal, and sagittal sections were obtained with 15 
contiguous slices with a slice thickness of 6.7 mm and a spatial 
resolution of 6.1 mm full-width at half-maximum (FWHM) in the 
center of the field of view. All data were reconstructed in a 
128x128 image matrix. The final in-plane resolution in recon- 
structed and Harm-filtered images with a cut-off frequency of 0.3 
cycles per pixel was approximately 8 mm FWHM. 
All dynamic and static PET images were taken and interpreted 
by two nuclear medicine specialists, including sagittal, coronal, 
and transverse sections. FDG-PET findings were compared with 
official dictated reports of CT and/or MRI findings, and evaluated. 
Tumor accumulation was classified into four grades: grade 0, 
normal: no abnormal accumulation; grade 1, probably normal: 
negative FDG scan; grade 2, probably abnormal: positive FDG 
scan; grade 3, definitely abnormal: positive FDG scan. 
Our visual interpretation criteria for establishing that the activ- 
ity was from the bladder cancer and not from the urine in the blad- 
der were as follows: correspondence with the lesion on CT and/or 
MRI, and earlier visualization with gradually increased accumula- 
tion on dynamic or influx images. 
The standardized uptake value (SUV) was defined as follows: 
SUV=decay-corrected dose/cc tumor/injected dose/patient 
weight (g). 
SUV images were reconstructed in 11 patients from projection da- 
ta obtained at 60-70 min following injection, and SUVs were cal- 
culated from regions of interest (ROIs) drawn on sites metaboli- 
cally representing the most active areas in tumors on images in 
each patient. The ROIs were usually 16 pixels in size. Tumor ac- 
cumulation was quantiatively evaluated by the SUVs. 
Influx images were generated as follows: An ROI was drawn 
around the femoral artery to create an input function curve. Then 
the Patlak parameters were calculated and fitted using the linear 
least-squares method from 5 to 60 min post injection for each pix- 
el in the dynamic image sequence. Fits were constrained so the 
correlation coefficient was 0.9 or greater [15]. 
Results 
All of the 12 patients were confirmed to have recurrent 
or residual tumor in the bladder and/or lymph node or 
distant organ metastasis. Overall, FDG-PET scanning 
was t rue -pos i t i ve  (p re sence  o f  foca l  F D G  uptake  re la t ive  
to su r round ing  t i ssue  up take)  in e igh t  o f  the  pa t ien ts  
(66 .7%) ,  but  f a l s e - n e g a t i v e  in fou r  (33 .3%)  (Table  1). O f  
20 o rgans  wi th  t u m o r  mass  l es ions  c o n f i r m e d  pathologi- 
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Table 1. Tumor characteristics and FDG-PET grading for each patient 
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Patient Age/sex Histological Radio- Period between 
no. type (grade) and/or tissue diagnosis 
chemotherapy and FDG-PET 
CT/MRI findings FDG-PET Final dignosis 
grading 
1 63/F TCC (3) + 7 years 
2 83/M TCC (3) - 7 months 
3 83/F TCC (3) - 3 months 
4 80/F TCC (2) - 2 months 
5 36/F TCC (3) - 1 month 
6 60/M TCC (3) - 4 years 9 months 
7 71/M TCC (3) ÷ 4 months 
8 55/F Adenoca. - 3 weeks 
9 58/M TCC (3) - 3 weeks 
10 66/M Pleomorphic - 2 weeks 
11 68/M TCC (3) + 8 months 
12 39/M TCC (3) + 4 months 
Bladder walt thickening 3 Recurrence 
Lymph node metastasis 3 Metastases 
Lung metastasis 3 Metastases 
Bladder wall thickening 2 Recurrence 
Bladder wall thickening 1 Recurrence 
Mass lesion in bladder 1 Recurrence 
Mass lesion in bladder 1 Recurrence 
Mass lesion in bladder 2 a Recurrence 
Lymph node metastasis 2 a Metastases 
Bladder wall thickening 1 Recurrence 
Lymph node swelling 1 Metastases 
Mass lesion in bladder 2 Residual tumor 
Mass lesion in bladder 3 Residual tumor 
Mass lesion in bladder 3 Residual tumor 
Normal 2 Recurrence c 
Rib metastases 3 b Confirmed 
Spine metastases 3 b Confirmed 
Patients 1-7 had undergone TUR-BT, patients 8-10, cystoscopic 
biopsy, and patients 11 and 12, radical cystectomy 
TCC, Transitional cell carcinoma; Adenoca., adenocarcinoma 
a Whole-body imaging 
b Whole-body and PET images revealed metastases of the cerivcal 
lymph nodes and sternum, as well as rib and spine metastases 
c Peritoneal carcinomatosis 
Fig. l. A transaxial FDG-PET image 
of the section through the vault of the 
bladder in a 63-year-old female (pa- 
tient no. 1) with recurrent cancer who 
had received radiotherapy and chemo- 
therapy. Recurrent tumor and regional 
lymph node metastasis (arrow) are 
well visualized 
cally or clinically, 16 (80%) were detected by F D G - P E T  
scanning.  All  of  the mult iple  metastatic lesions (17 foci) 
of  distant organs, inc luding the lung (eight foci), bone 
(eight foci), and a remote lymph node (one focus), were 
depicted in two patients. In patient  no. 12, F D G - P E T  
whole-body scan revealed mult iple  osseous metastases. 
F D G - P E T  scan visual ized one intrapelvic mass in pa- 
tient no. 11 with peri toneal carcinomatosis ,  who had a 
normal  f inding on CT. 
Urinary  tracer activity was present to some extent in 
the urinary system (bladder and bilateral ureter) in all of  
the patients. We were able to decrease the urinary F D G  
activity by urinary irrigation, but were unable  to reduce 
it to the background level. The internal  ur inary F D G  ac- 
tivity reduced the possibi l i ty of detecting lesions in the 
Fig. 2. Postvoid image after irrigation (/eft), static image 50-60 
rain following injection (middle), and influx image (right) in a 66- 
year-old male (patient no. 10) with pleomorphic sarcoma in the 
bladder. The postvoid image reveals most clearly the tumor local- 
ization of FDG (arrow) 
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Fig. 3. Distribution of the SUVs of primary (n=10) and metastatic 
(n=8) lesions of bladder tumors, compared with the SUVs (n=l 1) 
of the urine in the bladder and ureters 
tivity reduced the possibility of detecting lesions :in the 
urinary bladder and in the vicinity of the ureters. 
As for detection of regional lymph node metastasis by 
FDG-PET scanning, of three nodal lesions (of which two 
were histologically proven), two were detected by FDG- 
PET. In one patient (no. 8), extravesical extension, which 
CT scan was unable to detect, was depicted by FDG-PET 
and proven to be sigmoid colon invasion by pathology. 
With regard to detection of recurrent or residual tu- 
mor in the urinary bladder, FDG-PET scanning was ca- 
pable of detecting viable bladder cancer in six of the ten 
patients (60%). FDG-PET scanning was also capable of 
differentiating viable recurrent bladder cancer from radi- 
ation-induced thickening or necrosis of the bladder wall 
in two patients who received irradiation and chemothera- 
py (Fig. 1). 
However, FDG-PET scanning did not detect recur- 
rence in four patients (40%), principally because of in- 
tense accumulation of FDG excreted in the urinary blad- 
der. All of the patients showed moderate or intense accu- 
mulation of urinary FDG in the urinary bladder, despite 
saline irrigation of it. Post-void FDG imaging and Patlak 
graphical analysis proved capable of improving the qual- 
ity of pelvic FDG-PET images (Fig. 2). Influx images 
resulted in reduction of urinary FDG activity in two pa- 
tients. 
The calculated SUVs ranged from 2.19 to 8.94 
(4.55+2.20, n=10) in the primary sites, and from 1.47 to 
4.79 (3.06_1.19, n=8) in organ metastases; in the lymph 
node metastases the SUV averaged 3.64. The SUVs of 
the urine in the bladder and ureters ranged from 2.77 to 
8.88 (6.32_+1.62, n=l 1) (Fig. 3). 
Discussion 
It has been recognized that the precise staging of bladder 
cancer is of crucial importance in determining optimal 
cancer treatment and predicting prognosis. This is partic- 
ularly so in patients with bladder cancer, who frequently 
show a recurrent or persistent course. Basic principles of 
management require an accurate understanding of the lo- 
cation, extent, and viability of the disease during and af- 
ter treatment as well as the staging. However, as men- 
tioned above, abdominal ultrasonography, CT, and MRI, 
which are used in the management of bladder cancer, are 
not as accurate in staging as is pathological staging [1-7]. 
CT appears to be most widely used in the assessment of 
bladder carcinoma, but the accuracy of CT findings in re- 
spect of perivesical tumor growth or extension to contig- 
uous organs is only 64%-92% [3]. When using CT in the 
staging of bladder cancer, overstaging is more commonly 
observed than understaging. The reported accuracy of CT 
in detecting lymph node involvement ranges from 70% to 
90%, with false-negative rates of 25%--40% [4]. Dynam- 
ic contrast-enhanced MRI is more accurate than conven- 
tional MRI, although its staging accuracy is at best 75%, 
with the most common error being overstaging [16]. Ba- 
rentsz et al. reported that a three-dimensional technique 
using Tl-weighted magnetization prepared-rapid gradi- 
ent-echo resulted in a 15% improvement in staging [17]. 
However, these findings are only based on structural or 
anatomical alterations, and they do not reflect alteration 
in the metabolism of tumor tissues. Generally speaking, 
these modalities have poor capability for differentiating 
viable tumor mass from radiation-induced cystitis or ra- 
diation necrosis, although such differentiation is impor- 
tant in cases of bladder cancer with a persistent, protract- 
ed clinical course. After radiotherapy, the discordance be- 
tween clinical and pathological staging may approach 
50% due to both under- and overstaging [4]. 
On the other hand, it is conceivable that alteration in 
metabolism precedes morphological alteration. FDG, a 
glucose analog, has been extensively used as a tumor- 
scanning agent in PET metabolic studies. There is, how- 
ever, little clinical information regarding the utility of 
FDG-PET in bladder cancer. 
In our study we investigated the feasibility of per- 
forming FDG-PET in patients with bladder cancer. The 
detection rate achieved with FDG-PET scanning was 
66.7% (8 of 12 patients with bladder tumors), although 
four intravesical recurrent tumors could not be detected. 
Of 20 organs with tumor mass lesions confirmed patho- 
logically or clinically, 16 (80%) were detected by FDG- 
PET scanning. FDG-PET scanning depicted two of three 
regional lymph node metastases in three patients, and 
whole-body FDG imaging and FDG-PET scanning 
clearly revealed all of 17 multiple metastatic lesions in 
two patients. In one case direct invasion of the sigmoid 
colon, which could not be detected by CT scan, was de- 
picted by FDG-PET. These results suggest that it is fea- 
sible to use FDG-PET for clinical evaluation in patients 
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with bladder cancer, especially at advanced stages. From 
the viewpoint of potential cost-effectiveness, FDG-PET 
might be employed mainly in preoperative patients with 
probably positive findings on CT and/or MRI, since 
these modalities have a tendency toward overstanding 
[1-5, 7, 16, 17]. 
FDG-PET was very useful in detecting recurrent 
bladder cancer in two patients who had undergone radio- 
therapy and chemotherapy, because CT and MRI were 
unable to differentiate radiation necrosis from recurrent 
tumor. CT, which currently is the most commonly used 
diagnostic modality in bladder cancer, has a poor ability 
to discriminate recurrent cancer from certain benign dis- 
eases, i.e., radiation-induced bladder wall thickening or 
necrosis, and infectious cystitis with hematoma resulting 
from operative procedures. State-of-the-art MRI equip- 
ment also has difficulty in differentiating between radia- 
tion necrosis and tumor recurrence. The increase in FDG 
accumulation, if any, is well correlated with the number 
of viable cancer cells [18]. Given the high frequency of 
recurrence of bladder cancer after treatment, there is a 
possible role for FDG-PET in monitoring patients fol- 
lowing treatment. We believe that FDG-PET represents 
the examination of choice in patients with a mass lesion 
on CT or MRI after radiotherapy and/or chemotherapy, 
although our clinical experience is limited. 
A major problem with FDG-PET in imaging bladder 
cancer is the comparatively intense FDG accumulation 
due to excretion of FDG in the urine [t9]. Urinary excre- 
tion of FDG in dogs was 16% of the injected dose at 60 
min, and kidneys and urine have the hiLghest FDG uptake 
in the body, as measured in % injected dose/organ [20]. 
We performed retrograde irrigation of the urinary blad- 
der using saline irrigant and a Foley catheter before tak- 
ing PET images, but urinary activity overlying tumor ac- 
tivity is more or less inevitable on tomographic sections. 
One of the reasons why four patients with intravesical 
recurrent or residual tumor in our series had false-nega- 
tive FDG studies was probably the effect of urinary FDG 
activity. Thus, FDG-PET would not appear to have a 
strong likelihood of detecting bladder cancer of stages 0 
to C in the staging system proposed by Jewett-Strong- 
Marshall. However, stage D1, in which there is involve- 
ment of the contiguous organs and lymph nodes, might 
be adequately diagnosed by FDG-PET, as shown in pa- 
tient no. 1 (Fig. 1). It should be noted that urinary accu- 
mulation in the ureters may interfere with regional 
lymph node accumulation of FDG. 
Unfortunately, the SUVs calculated showed no differ- 
ences between tmnor tissue and urine, and thus proved 
of little additional value, although the SUVs of the urine 
did show a tendency to be greater than 5.0. 
Although urinary activity degraded FDG-PET image 
quality, influx images in two patients and a postvoid im- 
age in one patient reduced the apparent activity of FDG 
excretion in the urine. Thus, influx or postvoid images 
after irrigation appear promising techniques for improv- 
ing lesion detectability, in addition to saline irrigation. 
619 
Another method of lowering or diluting FDG activity in 
the urine, used by many other groups, is the preparation 
of an intravenous drip infusion of saline and/or diuretics 
prior to FDG administration. 
In summary, these preliminary data further indicate 
the feasibility of FDG-PET imaging of bladder cancer, 
although our study population was limited and did not 
include any patients who were true-negative for bladder 
cancer lesions. FDG-PET might be useful in detecting 
perivesical tumor growth or distant metastasis in patients 
with advanced bladder cancer, and for the early detec- 
tion of recurrent cancer following therapy, although a 
major remaining pitfall is the intense FDG accumulation 
due to excretion in the urine. Further prospective de- 
tailed studies of the FDG-PET method in patients with 
bladder tumors appear warranted, possibly including 
methods to reduce the urinary activity of FDG. 
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